Metabolites interact with microorganisms and vaccines

ABSTRACT: we engineered a β-glucan (Dex)-stabilized mulberry leaf lipid-based nanovaccine (DPML@OVA-CpG) that protected vaccine components during GI transit and facilitated their specific delivery to the GALTs. Following oral administration, the DPML@OVA-CpG underwent M cell-mediated transcytosis in the small intestine, activated immune responses within PPs and MLNs, and initiated mucosal and systemic anti-tumor immunity. In parallel, a fraction of the structurally intact nanovaccine persisted along the GI tract and reaches colorectal tumor regions, where near-infrared (NIR) irradiation leverages the carrier-enabled photothermal immunomodulation to induce immunogenic cell death (ICD). The released endogenous tumor-associated antigens (TAAs), together with the locally delivered CpG adjuvant, converted the tumor into an in situ vaccine, thereby establishing a secondary immune activation site within the colorectal TME (Scheme 1). This coordinated small intestinal priming-large intestinal boosting strategy overcomes tumor heterogeneity and synergizes with ICBs to achieve effective control of advanced CRC.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS15453 | MetaboLights | 2026-08-25

REPOSITORIES: MetaboLights